Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > REGULATORY
REGULATORY
- Medicoeconomic Assessment Should Initially Be Used in Reevaluating Existing Drugs: Dr Fukuda of NIPH
April 24, 2012
- HTA Should Be Used for NHI Drug Pricing, Not Reimbursement: Prof. Endo at DPJ Hearings
April 24, 2012
- PAFSC’s 2nd Committee Recommends Approval for Astellas’ Prostate Cancer Treatment, Japan's First IPV
April 23, 2012
- MHLW Aims to Begin IPV Vaccination in September: Health Minister Komiyama
April 23, 2012
- MHLW Issues Improvement Order to Pfizer for GMP Violation at US BVL Plant
April 20, 2012
- PAL Amendment: Proposal Emerges to Submit Legislation by Diet Members for Third Party Organization
April 19, 2012
- Discussions on Use of Cost-Effectiveness Assessments to Begin with Advanced but Costly Technologies: MED Director Suzuki
April 19, 2012
- DPJ Working Team to Hold Hearings on Cost-Effectiveness Assessments, Pricing of Long-Listed Drugs on April 20
April 19, 2012
- Risk Management Plans to Be Required from April 2013 to Strengthen Post-Marketing Safety Measures
April 18, 2012
- PAFSC’s 1st Committee to Discuss Approval for MTPC’s DPP-4 Inhibitor Tenelia at Meeting on April 27
April 17, 2012
- Members of Non-Partisan Study Group Support Generic Drug Use Requirement for Welfare Recipients
April 16, 2012
- CSIMC Expert Subcommittee to Begin Discussion on Long-Listed Drugs in June, Also Deliberate on Targets for Generic Products
April 13, 2012
- CSIMC to Set Up New Subcommittee on Medicoeconomic Assessments
April 13, 2012
- CSIMC Approves Listing of Samtirel Without Restriction on Prescription Period
April 12, 2012
- CSIMC Approves 12 APIs/21 Products; Listing Scheduled for April 17
April 12, 2012
- Life Innovation Subcommittee to Recommence Activities, Including 5-Year Strategy: DPJ Project Team
April 12, 2012
- 16 Add’l Prefectures to Participate in Introductory GMP Training Course in Kinki Region
April 11, 2012
- Personnel Exchange Between PMDA, Universities to Facilitate Drafting of GL for Reviewing Innovative Drugs: Deputy Director Miyata of ELD
April 11, 2012
- PMDA to Establish Forum for Discussions Between Reviewers and Outside Researchers to Upgrade Its Ability to Review Cutting-Edge Drugs
April 10, 2012
- MHLW Issues Development Requests for 80 Drugs/Indications with Unmet Medical Needs
April 10, 2012
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…